Free tool
FAERS Monitor: Benlysta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761043 or its brand name (Benlysta, Belimumab). Reports on generic versions are filed under their own applications.
Reports
32,030
Serious
13,657
43% of reports
Hospitalization
4,745
Death reported
907
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue5,154
- systemic lupus erythematosus3,979
- fatigue2,095
- drug ineffective1,857
- pain1,776
- wrong technique in device usage process1,635
- headache1,593
- nausea1,526
- malaise1,425
- product complaint1,411
- injection site pain1,388
- arthralgia1,380
- off label use1,118
- accidental exposure to product1,058
- exposure via skin contact1,029
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 132 |
| 2012 | 893 |
| 2013 | 711 |
| 2014 | 656 |
| 2015 | 1,107 |
| 2016 | 802 |
| 2017 | 1,033 |
| 2018 | 2,166 |
| 2019 | 2,969 |
| 2020 | 2,195 |
| 2021 | 2,402 |
| 2022 | 2,867 |
| 2023 | 3,400 |
| 2024 | 3,817 |
| 2025 | 5,198 |
| 2026 | 1,682 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,129 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| systemic lupus erythematosusSignal | 3,979 | 82.8 | 80.2 | 285,858 |
| product complaintSignal | 1,411 | 38.7 | 36.7 | 48,910 |
| exposure via skin contactSignal | 1,029 | 27.1 | 25.5 | 24,855 |
| wrong technique in device usage processSignal | 1,635 | 23.8 | 22.7 | 34,490 |
| product dose omission issueSignal | 5,154 | 11.7 | 11.4 | 50,225 |
| accidental exposure to productSignal | 1,058 | 6.8 | 6.4 | 5,201 |
| injection site painSignal | 1,388 | 3.0 | 2.8 | 1,843 |
| arthralgiaSignal | 1,380 | 2.2 | 2.1 | 899 |
| malaiseSignal | 1,425 | 2.1 | 2.0 | 877 |
| pain | 1,776 | 1.9 | 1.8 | 778 |
| fatigue | 2,095 | 1.8 | 1.7 | 725 |
| headache | 1,593 | 1.7 | 1.6 | 440 |
| nausea | 1,526 | 1.3 | 1.2 | 89 |
| drug ineffective | 1,857 | 0.9 | 0.9 | 12 |
| off label use | 1,118 | 0.8 | 0.8 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.